23 results on '"Batus M"'
Search Results
2. PO-1451 Neutrophil-lymphocyte ratio dynamics associated with survival after SBRT for stage I-II lung cancer
3. CO154 Ramucirumab+Docetaxel Post Immune Checkpoint Inhibitors (ICIS) and Platinum-Based Chemotherapy (CHEMO) in Advanced or Metastatic Non-Small Cell Lung Cancer (ANSCLC): Learnings from the Treat-Lung Observational Study
4. OA10.02 Psychosocial Distress in Patients with Driver-Mutant Lung Cancer
5. P76.30 The Neutrophil-to-Lymphocyte Ratio is a Prognostic Biomarker in Patients with EGFR Mutated Advanced NSCLC
6. P1.21 RNA Pathway Enrichment in Serum Based Mass Spectroscopy Prognostic Analyses
7. P1.02 Chemotherapy with VMAT (Volumetric Modulated Arc Therapy) Radiation Therapy For Poor Risk Stage IIIA-C NSCLC Patients
8. P1.05 Clinical Factors Associated with Progression in Previously Treated Patients with Metastatic NSCLC on ANTI-PD-1 Therapy
9. OA01.02 Prognostic Value of Baseline Autoantibodies in Metastatic NSCLC Patients Receiving PD-/PDL-1 Targeted Immunotherapy
10. OA03.01 Biomarkers of Autoimmune Toxicity in Metastatic SCLC Patients Receiving PD-1/PDL-1 Targeted Therapy
11. P2.04-69 Impact of Antibiotic Usage on Survival During Checkpoint Inhibitor Treatment of Non-Small Cell Lung Cancer (NSCLC)
12. P2.03-29 Circulating Levels of Ligands for Receptor Tyrosine Kinases May Contribute to an Immunosuppressive Tumor Microenvironment
13. MA13.01 Associations Between Baseline Serum Biomarker Levels and Cachexia/Pre-Cachexia in Pretreated Non-Small Cell Lung Cancer (NSCLC) Patients
14. PO-0776 Neutrophil-to-lymphocyte ratio dynamics predict for survival in lung cancer treated with SBRT
15. P3.01-19 Sequencing of Ramucirumab+Docetaxel Post-Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Patients
16. P3.01-05 Mature Progression-Free Survival in Stage IV Non-Small Cell Lung Cancer Patients Treated With Pemetrexed Maintenance Therapy
17. P2.12-16 Significant Tumor Regression and Toxicity with Nivolumab Plus Ipilimumab in Small Cell Lung Cancer Patients Following Radiation
18. P2.01-61 Body Mass Index over Time is Associated with Overall Survival in Advanced NSCLC Patients Treated with Immunotherapy.
19. P2.01-34 Prognostic Value of Neutrophil to Lymphocyte Ratio for Metastatic NSCLC Patients Treated with Immunotherapy and Ramucirumab Plus Docetaxel.
20. P2.01-12 Ramucirumab+Docetaxel Usage Following Rapid Disease Progression in Real World Advanced Non-Small Cell Lung Cancer Patients
21. PUB057 Neutrophil to Lymphocyte Ratio Predicts Survival in Advanced NSCLC Patients Treated with Second-Line PD-1 Immune Checkpoint Inhibitors
22. PS02.13 Rapid Progression in 100% PDL-1 expressing NSCLC: Topic: Medical Oncology
23. 1442 - Survival Prediction in Ambulatory Stage III/ IV Non Small Cell Lung Cancer Patients Using the Palliative Performance Scale, Ecog and Lung Cancer Symptom Scale
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.